Objective To document the decline of upper and lower limb functions, mobility, and independence in daily living activities in adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) over a 2-year period.
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a progressive, hereditary disorder caused by mutations in the SACS gene 1 located on chromosome 13q12. ARSACS was first described in the Saguenay-LacSaint-Jean and Charlevoix regions of Quebec (Canada). Worldwide, it is the most frequent recessive ataxia after Friedreich ataxia. ARSACS is characterized by the presence of symptoms in each of these 3 main components: pyramidal, cerebellar, and neuropathic. This characteristic leads to a large number of signs and symptoms with a high level of variability among individuals in terms of clinical presentation, severity, and progression. Manifestations include incoordination, impaired dexterity, gait ataxia, spasticity, and weakness, among others. [2] [3] [4] [5] [6] The only published study addressing the evolution of ARSACS was conducted by Duquette et al. 6 In this retrospective study, the team documented the evolution of gait/ appendicular ataxia, spasticity, and neuropathy during childhood (before 18 years of age). Disease progression during adulthood has never been documented with a longitudinal design and standardized quantitative assessments. As pointed out by a recent US Food and Drug Administration report, studies documenting natural history are essential to improve our knowledge of prognosis and to better plan rehabilitation interventions and future clinical trials.
The aim of this study was to document the decline of upper and lower limb functions, mobility, and independence in daily living activities in adults with ARSACS over a 2-year period.
Methods

Study design
This was an exploratory longitudinal study.
Subjects
Participants were recruited in 2013 among patients followed up at the Neuromuscular Clinic of the Centre intégré universitaire de santé et de services sociaux du Saguenay-LacSaint-Jean (Québec, Canada). Inclusion criteria were age between 18 and 59 years, homozygote for the c.8844delT mutation in the SACS gene, and able to provide informed consent.
Standard protocol approvals, registrations, and patient consents The study was approved by the Ethics Review Board of the Centre intégré universitaire de santé et de services sociaux Saguenay-Lac-Saint-Jean, and written informed consent was obtained from each participant.
Data collection
Participants were assessed 2 years apart by the same 2 physical therapists at both time points using standardized operational procedures. All assessments were conducted during 3 half-day sessions (within a maximum interval of 2 weeks) at both baseline and follow-up. Data on age, sex, mobility level, and walking aids used were collected. Disease stage of the participants was determined from their mobility level and the use of walking aid (according to the Scale for the Assessment and Rating of Ataxia [SARA] development study 7 ) as follows: stage 1, no walking difficulty without any walking aid; stage 2, first walking difficulty, no walking aid; stage 3, walking with aid or support; and stage 4, using a wheelchair.
Outcome measures
Upper limb coordination was assessed with the Standardized Finger Nose Test (SFNT). 4 Fine dexterity was measured with the Nine-Hole Peg Test (NHPT). 8 Intrarater and interrater reliability of these tests was excellent (intraclass correlation coefficient [ICC] = 0.90-0.98), and their construct validity has been demonstrated in ARSACS. 9 Lower limb coordination was measured with the Lower Extremity Motor Coordination Test (LEMOCOT). 10, 11 The intrarater and interrater reliability of the LEMOCOT and its construct validity are excellent in ARSACS (ICC = 0.92-0.97).
11 Balance was assessed with the Berg Balance Scale, 12 the construct validity of which was demonstrated in ARSACS. 13 Walking ability was documented in terms of walking speed with the 10-m walk test (10mWT) at comfortable pace, and long-distance walking was assessed with the 6-minute walk test (6MWT). 14 Both tests (10mWT and 6MWT) have excellent interrater reliability (ICC = 0.97-0.99), and construct validity was confirmed in the ARSACS population. 13 Overall disease severity was measured with the SARA. 7 Its interrater reliability is excellent (ICC = 0.97) in spinocerebellar ataxia 7 and in recessive ataxia or nonprogressive cerebellar ataxia (ICC = 0.98). 15 Independence in daily living activities was measured with the Barthel Index. 16 Its validity and reliability in recessive ataxia are not known.
Statistical analysis
Data are expressed as mean ± SD for continuous variables and as frequency and percentage for categorical variables. When >1 trial was performed, the mean was used for analyses (SFNT, NHPT, LEMOCOT, 10mWT). Only results from the dominant hand/foot are presented here. Comparison between follow-up and baseline performance was made with the Glossary ARSACS = autosomal recessive spastic ataxia of Charlevoix-Saguenay; ICC = intraclass correlation coefficient; LEMOCOT = Lower Extremity Motor Coordination Test; NHPT = Nine-Hole Peg Test; SARA = Scale for the Assessment and Rating of Ataxia; SFNT = Standardized Finger Nose Test; 6MWT = 6-minute walk test; 10mWT = 10-m walk test.
nonparametric Wilcoxon signed-rank test because the number of participants was <30. A value of p < 0.05 was considered significant. In addition, normality of the distribution of the difference was verified with the Kolmogorov-Smirnov statistic. Significant differences between follow-up and baseline were compared against the SEM of each outcome measure. 7, 9, 11, 13, 17 Data were analyzed with IBM SPSS Statistics for Windows, version 24.0 (IBM Corp, Armonk, NY).
Data availability
Anonymized data will be shared by request from any qualified investigator.
Results
From the 28 participants at baseline, 19 participated in the follow-up. Reasons not to participate were lack of time (44.4%), lack of interest (44.4%), and health issues (11.1%). Individuals who refused to participate in the follow-up were not different from those who participated in terms of age (37.7 vs 38.8 years, p = 0.664), sex (56% vs 58% men, p = 0.612), and disease stage (p = 0.442). All participants' characteristics are presented in table 1. The mean age of the 19 participants at baseline was 38.3 years, and 58% were men. Eighteen participants were right-handed.
Comparisons of performance between follow-up and baseline are presented in table 2.
Lower limb coordination, balance, and walking ability significantly decreased during the 2-year period, and overall disease severity became worse; all these results are beyond measurement error. In addition, the distribution of differences was normal for all measures (p > 0.05) except for the NHPT (p = 0.001). According to walking ability results, an important percentage of participants lost their ability to perform walking tests at follow-up (10mWT 21.4% [3 of 14] , 6MWT 28.6% [4 of 14] ).
Discussion
A large population of people with ARSACS live in the Saguenay-Lac-Saint-Jean region, and an increasing number of people with recessive ataxias are now diagnosed as having ARSACS worldwide. Results of this first prospective natural history study will help clinicians to better inform their patients about disease progression. Despite the relatively small number of participants, we found a significant decline in lower limb coordination, balance, and walking ability, as well as an increase in overall disease severity, over 2 years. All results were beyond outcome measure measurement error. In addition, the normality of the distribution of the differences indicates that the presence of outliers did not significantly affect the results. These exploratory results will help plan future clinical trials in regard to the selection of outcome measures. Given the slow progression of the disease, the selection of outcome measures must be based on their sensitivity and accuracy to detect small changes. Otherwise, the tool can fail to detect a change that appears in the participant, or a significant difference can be found but reflects only the associated measurement error.
Regarding the absence of a significant decline of upper limb dexterity and coordination measured by the SFNT and NHPT, we hypothesize that participants were so impaired at baseline that they could not deteriorate further at follow-up (floor effect). Effectively, the mean number of targets touched in the SFNT by participants with ARSACS was less than half of that of healthy elderly people (women 11.5 and men 10.7 compared to 23.2 and 24.2 18 ), well illustrating the high level of impairment present in people with ARSACS. The same portrait is observed for the NHPT; participants in this study took an average of 58 seconds to complete the task compared to an average of 20.4 seconds for healthy elderly women and 22.4 seconds for healthy elderly men. 19 However, given the small sample size, we cannot exclude a lack of power. Other outcome measures must be explored in this population to better track the decrease of upper limb functions. This is the first study documenting prospectively the decline in functions in ARSACS. The small sample size limits the generalization of the results; individuals who accepted to participate in the study may be different in other characteristics from the ones who refused. However, the availability of metrologic properties for most outcome measures has permitted documentation of the SEM and has ensured that the changes were beyond measurement error. The next step will be to document the responsiveness of these outcome measures. In addition, the longitudinal documentation of ARSACS impairments must be continued with a larger cohort to take into account individual variability and with a longer period of time to have a better understanding of the disease progression. Abbreviations: BBS = Berg Balance Scale; LEMOCOT = Lower Extremity Motor Coordination Test; NHPT = Nine-Hole Peg Test; SARA = Scale for the Assessment and Rating of Ataxia; SFNT = Standardized Finger Nose Test; 6MWT = 6-minute walk test; 10mWT = 10-m walk test. a Variation in number of participants can be explained by the inability to perform a test at follow-up and incomplete data. b Difference = T2 − T1; use of a negative sign implies a decrease in the performance over 2 years except for the NHPT and SARA. c Significance of the difference between baseline and follow-up was determined with the Wilcoxon signed-rank test.
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